alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Oncogenic Mutations'],"[{'ncitCode': 'C179323', 'drugName': 'Lunresertib'}, {'ncitCode': 'C174206', 'drugName': 'Camonsertib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 880, 'code': '', 'color': 'LightBlue', 'name': '', 'mainType': {'id': None, 'name': 'Ovarian Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Ovary/Fallopian Tube', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['38410486'],"[{'link': 'https://aacrjournals.org/mct/article/22/12_Supplement/B057/730329/Abstract-B057-Preclinical-development-of-PKMYT1)(Abstract', 'abstract': 'Gallo, D. et al., Abstract# B057, AACR 2023.'}, {'link': 'https://www.reparerx.com/wp-content/uploads/2023/10/ANE_B156_MYTHIC-clinical_poster.pdf', 'abstract': '# B156, AACR-NCI-EORTC 2023.'}, {'link': 'https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852', 'abstract': 'Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023.'}]","Lunresertib is an orally available, small molecule PKMYT1 inhibitor and camonsertib is an orally available, small molecule ATR inhibitor. There are promising clinical data of response to lunresertib plus camonsertib in patients with FBXW7-mutated gynecologic cancers. In the Phase I MYTHIC (NCT04855656) trial of lunresertib plus camonsertib in patients with advanced tumors harboring CCNE1 amplifications, FBXW7 deleterious mutations or PPP2R1A deleterious mutations, the lunresertib plus camonsertib cohort (n=59 [n=17, endometrial; n=13, colorectal; n=11, ovarian; n=3, breast; n=3, lung; n=12, other]) demonstrated an overall response rate of 23.6% in all evaluable patients across tumor types, with a 17.4% response rate in patients with FBXW7-amplified tumors and a 38.5% response rate in patients with gynecologic cancers across all dosages (Abstract: Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023. https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852). Preclinical studies with ovarian and endometrial cancer cell lines and xenograft models expressing FBXW7 mutations demonstrate sensitivity to lunresertib plus camonsertib as measured by tumor regression and decreased cellular viability (PMID: 38410486) (Abstract: Gallo, D. et al., Abstract# B057, AACR 2023. https://aacrjournals.org/mct/article/22/12_Supplement/B057/730329/Abstract-B057-Preclinical-development-of-PKMYT1)(Abstract: Yap, T. et al., Abstract# B156, AACR-NCI-EORTC 2023. https://www.reparerx.com/wp-content/uploads/2023/10/ANE_B156_MYTHIC-clinical_poster.pdf)."
['Oncogenic Mutations'],"[{'ncitCode': 'C179323', 'drugName': 'Lunresertib'}, {'ncitCode': 'C174206', 'drugName': 'Camonsertib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 884, 'code': '', 'color': 'PeachPuff', 'name': '', 'mainType': {'id': None, 'name': 'Endometrial Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Uterus', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['38410486'],"[{'link': 'https://aacrjournals.org/mct/article/22/12_Supplement/B057/730329/Abstract-B057-Preclinical-development-of-PKMYT1)(Abstract', 'abstract': 'Gallo, D. et al., Abstract# B057, AACR 2023.'}, {'link': 'https://www.reparerx.com/wp-content/uploads/2023/10/ANE_B156_MYTHIC-clinical_poster.pdf', 'abstract': '# B156, AACR-NCI-EORTC 2023.'}, {'link': 'https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852', 'abstract': 'Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023.'}]","Lunresertib is an orally available, small molecule PKMYT1 inhibitor and camonsertib is an orally available, small molecule ATR inhibitor. There are promising clinical data of response to lunresertib plus camonsertib in patients with FBXW7-mutated gynecologic cancers. In the Phase I MYTHIC (NCT04855656) trial of lunresertib plus camonsertib in patients with advanced tumors harboring CCNE1 amplifications, FBXW7 deleterious mutations or PPP2R1A deleterious mutations, the lunresertib plus camonsertib cohort (n=59 [n=17, endometrial; n=13, colorectal; n=11, ovarian; n=3, breast; n=3, lung; n=12, other]) demonstrated an overall response rate of 23.6% in all evaluable patients across tumor types, with a 17.4% response rate in patients with FBXW7-amplified tumors and a 38.5% response rate in patients with gynecologic cancers across all dosages (Abstract: Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023. https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852). Preclinical studies with ovarian and endometrial cancer cell lines and xenograft models expressing FBXW7 mutations demonstrate sensitivity to lunresertib plus camonsertib as measured by tumor regression and decreased cellular viability (PMID: 38410486) (Abstract: Gallo, D. et al., Abstract# B057, AACR 2023. https://aacrjournals.org/mct/article/22/12_Supplement/B057/730329/Abstract-B057-Preclinical-development-of-PKMYT1)(Abstract: Yap, T. et al., Abstract# B156, AACR-NCI-EORTC 2023. https://www.reparerx.com/wp-content/uploads/2023/10/ANE_B156_MYTHIC-clinical_poster.pdf)."
['Oncogenic Mutations'],"[{'ncitCode': 'C179323', 'drugName': 'Lunresertib'}, {'ncitCode': 'C174206', 'drugName': 'Camonsertib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],['38410486'],"[{'link': 'https://aacrjournals.org/mct/article/22/12_Supplement/B057/730329/Abstract-B057-Preclinical-development-of-PKMYT1)(Abstract', 'abstract': 'Gallo, D. et al., Abstract# B057, AACR 2023.'}, {'link': 'https://www.reparerx.com/wp-content/uploads/2023/10/ANE_B156_MYTHIC-clinical_poster.pdf', 'abstract': '# B156, AACR-NCI-EORTC 2023.'}, {'link': 'https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852', 'abstract': 'Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023.'}]","Lunresertib is an orally available, small molecule PKMYT1 inhibitor and camonsertib is an orally available, small molecule ATR inhibitor. There are promising laboratory and anecdotal clinical data to support use of lunresertib plus camonsertib in patients with FBXW7-mutated solid tumors. In the Phase I MYTHIC (NCT04855656) trial of lunresertib plus camonsertib in patients with advanced tumors harboring CCNE1 amplifications, FBXW7 deleterious mutations or PPP2R1A deleterious mutations, the lunresertib plus camonsertib cohort (n=59 [n=17, endometrial; n=13, colorectal; n=11, ovarian; n=3, breast; n=3, lung; n=12, other]) demonstrated an overall response rate of 23.6% in all evaluable patients across tumor types (n=55), with a 17.4% response rate in patients with FBXW7-mutated tumors (n=23), a confirmed partial response (PR) in a patient with FBXW7-mutated colorectal cancer and an unconfirmed PR in a patient with FBXW7-mutated breast cancer (Abstract: Yap, T. et al., Abstract# 35396. AACR-NCI-EORTC 2023. https://ir.reparerx.com/static-files/c46f541b-554a-4690-90de-e63fa7dea852). Preclinical studies with ovarian and endometrial cancer cell lines and xenograft models expressing FBXW7 mutations demonstrate sensitivity to lunresertib plus camonsertib as measured by tumor regression and decreased cellular viability (PMID: 38410486) (Abstract: Gallo, D. et al., Abstract# B057, AACR 2023. https://aacrjournals.org/mct/article/22/12_Supplement/B057/730329/Abstract-B057-Preclinical-development-of-PKMYT1)(Abstract: Yap, T. et al., Abstract# B156, AACR-NCI-EORTC 2023. https://www.reparerx.com/wp-content/uploads/2023/10/ANE_B156_MYTHIC-clinical_poster.pdf)."
